A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Descripteurs (mots clés)
Thésaurus Mesh
> D > dysfonctionnement des glandes de Meibomius
dysfonctionnement des glandes de Meibomius
Ajouter le résultat dans votre panier Affiner la recherche
Etendre la recherche sur niveau(x) vers le bas
Association between Dyslipidemia and Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis / Prince K. Akowuah in OVS : Optometry & Vision Science, vol. 100, 03 (Mars 2023)
[article]
in OVS : Optometry & Vision Science > vol. 100, 03 (Mars 2023)
Titre : Association between Dyslipidemia and Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis Type de document : article de périodique Auteurs : Prince K. Akowuah ; Ebenezer Owusu ; Esther Nutifafa Senanu ; Joseph Adjei-Anang Année de publication : 2023 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Dyslipidémies
[Thésaurus Mesh]Méta-analyse
[Thésaurus Mesh]Revue de la littérature
[Thésaurus Mesh]Syndromes de l'oeil secMots-clés : meibum lipides lacrymaux Résumé : SIGNIFICANCE: Meibomian gland dysfunction reduces the quality and/or quantity of meibum. An association between dyslipidemia and meibomian gland dysfunction has been proposed, but this has not been estimated. Therefore, this study evaluates the odds of dyslipidemia in meibomian gland dysfunction. PURPOSE: This study aimed to use meta-analysis to estimate the association between dyslipidemia and meibomian gland dysfunction. METHODS: The following databases were searched: PubMed, Google Scholar, and Scopus. Case-control and cohort studies assessing the association between dyslipidemia and meibomian gland dysfunction were included. The association was assessed using odds ratios. Heterogeneity between studies was assessed with the χ2 statistic and degree of inconsistency. The quality of studies was assessed using the Newcastle-Ottawa Scale. The systematic review was registered on PROSPERO (ID: CRD42022347982). RESULTS: The systematic review included three case-control and two cohort studies. The odds of hypercholesterolemia and hypertriglyceridemia in meibomian gland dysfunction were 5.45 (95% confidence interval [CI], 1.65 to 17.95) and 3.28 (95% CI, 1.25 to 8.62), respectively. The odds of elevated serum low-density lipoprotein and reduced high-density lipoprotein in meibomian gland dysfunctionwere 2.72 (95% CI, 1.24 to 5.98) and 1.15 (95% CI, 0.74 to 1.79), respectively. The current study's limitation is that the effects of sex, age, and meibomian gland dysfunction severity on the association between dyslipidemia and meibomian gland dysfunction were not assessed. CONCLUSIONS: The current study suggests a significant association between dyslipidemia and meibomian gland dysfunction. This finding suggests that meibomian gland dysfunction diagnosis may call for dyslipidemia screening. Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study / Gina Wesley in OVS : Optometry & Vision Science, vol. 99, 04 (Avril 2022)
[article]
in OVS : Optometry & Vision Science > vol. 99, 04 (Avril 2022)
Titre : Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study Type de document : article de périodique Auteurs : Gina Wesley ; Katherine M. Bickle ; Johnathon Downing ; Bret Fisher ; Brennan Greene ; Colton Heinrich ; David Kading ; Shane R. Kannarr ; Jason Miller ; Satish Modi ; David Ludwick ; Joseph Tauber ; Sruthi Srinivasan ; Venkiteshwar Manoj Année de publication : 2022 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Recherche comparative sur l'efficacité
[Thésaurus Mesh]Syndromes de l'oeil sec
[Thésaurus Mesh]ThérapeutiqueMots-clés : Système de pulsations thermiques Résumé : SIGNIFICANCE: Given the significance of meibomian gland dysfunction subjects in evaporative dry eye, its chronic
and progressive nature, limited promising treatment options, and novel treatment techniques are important. This
randomized clinical study evaluated the noninferiority of SYSTANE iLux with LipiFlow in meibomian gland dysfunction treatment at 12 months.
PURPOSE: This study aimed to demonstrate noninferiority of SYSTANE iLux compared with LipiFlow at 12 months
after single treatment in meibomian gland dysfunction subjects with evaporative dry eye.
METHODS: In this prospective, randomized, multicenter, assessor-masked, parallel-group trial, subjects (N = 236;
aged ≥18 years) with meibomian gland score (MGS) of ≤12 in lower eyelids, noninvasive tear breakup time (NITBUT;
first breakup) of <10 seconds, and Impact of Dry Eye on Everyday Life—Symptom Bother (IDEEL-SB) module score
of >16 were randomized (1:1) to receive SYSTANE iLux (n = 119) or LipiFlow (n = 117). Subjects attended a total
of eight visits, including screening, treatment, and follow-up visits at 2 weeks and at 1, 3, 6, 9, and 12 months/
exit, to evaluate change from baseline in MGS, NITBUT, IDEEL-SB module score, and safety outcomes.
RESULTS: A total of 227 subjects completed the study (mean ± standard deviation age, 57.3 ± 13.8 years). At
12 months, least squares mean change from baseline in MGS was similar between iLux and LipiFlow
(17.4 ± 1.97 vs. 17.8 ± 1.98). Noninferiority of SYSTANE iLux compared with LipiFlow in change from baseline
in MGS (95% lower confidence limit of least squares mean difference, >−5), NITBUT (>−2.5 seconds), and
IDEEL-SB score (95% upper confidence limit, <12) was achieved at all post-treatment visits. No other serious ocular or device-related adverse events were reported.
CONCLUSIONS: The treatment outcomes with SYSTANE iLux were noninferior to LipiFlow during the 12-month
follow-up in subjects with dry eye–associated meibomian gland dysfunction.Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire Eyelid health: management of itchy, sticky and swollen lids / Sandeep Kaur Dhallu in OPTOMETRY TODAY, vol. 63, 06 (Novembre-décembre 2023)
[article]
in OPTOMETRY TODAY > vol. 63, 06 (Novembre-décembre 2023) . - p. 48-51
Titre : Eyelid health: management of itchy, sticky and swollen lids Type de document : article de périodique Auteurs : Sandeep Kaur Dhallu Année de publication : 2023 Article en page(s) : p. 48-51 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:M:Maladies de la paupière:Maladies de la paupière / prévention et contrôle
[Thésaurus Mesh]Blépharite
[Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Hygiène
[Thésaurus Mesh]Maladies de la paupière
[Thésaurus Mesh]Paupières
[Thésaurus Mesh]Syndromes de l'oeil secRésumé : [...]Les praticiens sont régulièrement confrontés à des troubles des paupières, les patients présentant souvent un dysfonctionnement des glandes de Meibomius (MGD), une blépharite et une sécheresse oculaire. Beaucoup de ces troubles sont affectés par des médiateurs inflammatoires. L'hygiène des paupières, qui intègre le nettoyage et le massage des paupières, est un traitement bien accepté pour bon nombre de ces troubles et peut faire partie d'un régime de soins plus large comprenant d'autres options de prise en charge. [...]
Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité O Périodique Erasme - périodiques Périodiques Disponible Localized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time / Thomas Chester in OVS : Optometry & Vision Science, vol. 100, 09 (Septembre 2023)
[article]
in OVS : Optometry & Vision Science > vol. 100, 09 (Septembre 2023)
Titre : Localized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time Type de document : article de périodique Auteurs : Thomas Chester ; Tanner Ferguson ; Emma Chester Année de publication : 2023 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]Collecte de données
[Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Ophtalmologie
[Thésaurus Mesh]Optométrie
[Thésaurus Mesh]Résultat thérapeutique
[Thésaurus Mesh]Signes et symptômes
[Thésaurus Mesh]ThérapeutiqueMots-clés : Traitement thermique localisé Résumé : SIGNIFICANCE
Meibomian gland dysfunction (MGD) can produce a myriad of symptoms. The effective treatment of MGD can reduce the burden of this condition. Although several studies have indicated that TearCare (Sight Sciences, Menlo Park, CA) is an effective treatment for MGD, no studies currently provide information regarding the duration of efficacy.
PURPOSE
The purpose of this analysis was to determine the duration of efficacy of symptom relief and improvement of signs (as measured by gland function) for a treatment consisting of controlled heating of the meibomian glands using SmartLids (Sight Sciences) combined with manual expression of the liquefied meibum by a physician.
METHODS
This study involved retrospective analysis of data gathered from a single-center ophthalmology/optometry practice. Symptoms were assessed using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and the signs were assessed using the meibomian gland expression (MGE) scores before and at several time points (8 weeks, 6 months, 12 months, and 18 months). Further analysis evaluating the efficacy in subgroups based on age, race, and sex was performed.
RESULTS
There were 78 patients included in this study. The mean baseline SPEED score decreased from 14 to 7.9 at 8 weeks. The mean SPEED scores at 6 and 12 months were maintained at 7.7 and 7.9, respectively, and at 18 months went to 8.9. At baseline, the mean MGE was 4.9 in the right eye and 4.8 in the left eye. In both eyes, the mean MGE increased to 9.0 in both eyes at 8 weeks. At 6 months, the mean MGE score was maintained at 8.6 in the right and 8.2 in the left and remained consistent at 12 months with 7.8 in the right and 7.8 in the left. At 18 months, the MGE score went to 6.8 in the right eye and 7.0 in the left eye.
CONCLUSIONS
A single TearCare treatment effectively reduced both the symptoms and signs of MGD and maintained its effects for 12 months.Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire The Influence of Pterygium on Meibomian Glands and Dry Eye Parameters / Ali Devebacak in OVS : Optometry & Vision Science, vol. 100, 03 (Mars 2023)
[article]
in OVS : Optometry & Vision Science > vol. 100, 03 (Mars 2023)
Titre : The Influence of Pterygium on Meibomian Glands and Dry Eye Parameters Type de document : article de périodique Auteurs : Ali Devebacak ; Mehmet Esat Teker ; Melis Palamar Année de publication : 2023 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Ptérygion
[Thésaurus Mesh]Syndromes de l'oeil secRésumé : SIGNIFICANCE: Mechanical factors are also associated with meibomian gland dysregulation in patients with pterygium. Dry eye parameters were assessed, and the results support the association between pterygium and dry eye disease. PURPOSE: This study aimed to investigate how meibomian gland dysfunction and dry eye parameters relate to the existence of pterygium. METHODS: Patients with pterygium and healthy volunteers of similar age and demographic characteristics were included. Schirmer 1 test, Ocular Surface Disease Index score, fluorescein tear film breakup time, and ocular surface staining scores (Oxford score) were recorded. Meiboscores were estimated based on meibomian gland loss rate on infrared meibography (SL-D701; Topcon, IJssel, the Netherlands). The symmetry of meibomian gland loss with respect to eyelid midline was assessed. RESULTS: Fifty-four eyes with pterygium (group 1) and 50 eyes of healthy volunteers (group 2) were included. The mean ages were 54.0 ± 12.3 and 52.3 ± 8.0 years, respectively. Schirmer 1 test results and tear film breakup time were lower in group 1 (P = .007, P < .001). Oxford and Ocular Surface Disease Index scores were significantly higher in group 1 (P = .009, P < .001). The mean meiboscores were significantly higher in group 1 (P < .001). There was meibomian gland depletion in 90.7% (49 of 54) of group 1 and 32% (16 of 50) of group 2 (P < .001). Meibomian gland loss region was distributed asymmetrically in 75.5% (37 of 49) of the eyes in group 1, but not in any of the eyes in group 2. The asymmetry was located on the side where the pterygium was detected in 94.5% (35 of 37) of these eyes. CONCLUSIONS: Meibomian glands are influenced morphologically and functionally in eyes with pterygium. The overlap of the pterygium location and meibomian gland abnormality suggests a direct mechanical relationship. In managing pterygium patients, the possibility of meibomian gland dysfunction and associated evaporative dry eye should be considered Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire